M13 Phage Peptide Display for Aβ Oligomer Detection Across BBB
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunohistochemical tools are incapable of selectively detecting soluble oligomeric and fibrillar forms of amyloid beta (Aβ) in brain samples, which are toxic species implicated in Alzheimer's disease, while existing peptides cannot cross the blood-brain barrier.
Innovation Solution
Engineered M13 bacteriophages are genetically modified to display amyloidogenic peptide motifs from Aβ42 on their surface, allowing them to recognize and neutralize Aβ oligomers and fibrils, and are used as diagnostic and therapeutic agents to inhibit their aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If peptides are used to detect Aβ oligomers and fibrils, then detection selectivity is improved, but the ability to cross the blood-brain barrier is lost
Solution Approach 1:
The patent uses bacteriophage M13 as an intermediary carrier that displays peptide motifs on its surface. The phage particle itself crosses the blood-brain barrier while presenting the peptide detection motif, thus mediating between the peptide's detection function and the need for BBB penetration. This resolves the contradiction by separating the crossing function (phage particle) from the detection function (peptide motif).
2Measurement precision
If immunohistochemical tools are used to detect Aβ, then detection capability is improved, but the ability to detect soluble oligomeric forms is lost
Solution Approach 1:
The patent applies local quality by engineering specific peptide motifs (Aβ30-39 and Aβ33-42) at specific locations on the phage surface to recognize specific conformational epitopes of Aβ oligomers. This localized functional design enables selective detection of soluble oligomeric forms while maintaining overall detection capability.
3Measurement precision
If peptides are engineered to recognize Aβ oligomers, then detection specificity is improved, but immunochemical labeling capability is lost
Solution Approach 1:
The patent merges the detection specificity of engineered peptides with the immunochemical labeling capability of antibodies by displaying multiple copies of the peptide motif on the phage surface. The phage-peptide complex can be detected using anti-phage antibodies, thus combining peptide specificity with antibody labeling ease.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered M13 bacteriophages effectively detect and inhibit Aβ oligomers and fibrils, providing early detection and potential treatment of Alzheimer's disease by reducing their aggregation, and can cross the blood-brain barrier.
Implementation Method 1
synthetic phages that display surface peptide motifs known to recognize Aβ42 conformers via homotypic interactions
Implementation Method 2
M13 is able to cross the BBB
Implementation Method 3
inhibition of this step is a main target in approaches aimed at limit Aβ aggregation and toxicity
Implementation Method 4
the majority of toxic species are generated from the secondary nucleation of Aβ monomers on the surfaces of amyloid fibrils
Data Source
AI summary
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.